Across TCGA pan-cancer cohorts, GLI4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GLI4 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GLI4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLI4 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.
UCEC, LIHC, and LUSC are the cancer types where GLI4 Mutation most reproducibly stratifies survival.